How many cardiovascular events can be prevented with optimal management of high-risk Canadians? - Wikidata - awgldk - TriplyDB

How many cardiovascular events can be prevented with optimal management of high-risk Canadians?

How many cardiovascular events can be prevented with optimal management of high-risk Canadians?

http://www.wikidata.org/entity/Q37098243

about

Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS)

P2860

Q34338656-A1D3FD86-C3D6-492B-95B0-85649936D2A8

P2860

How many cardiovascular events can be prevented with optimal management of high-risk Canadians?

http://www.wikidata.org/entity/Q37098243

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

How many cardiovascular events ...... gement of high-risk Canadians?

@en

How many cardiovascular events ...... gement of high-risk Canadians?

@nl

type

label

How many cardiovascular events ...... gement of high-risk Canadians?

@en

How many cardiovascular events ...... gement of high-risk Canadians?

@nl

prefLabel

How many cardiovascular events ...... gement of high-risk Canadians?

@en

How many cardiovascular events ...... gement of high-risk Canadians?

@nl

P1433

Q37098243-A2E32D1D-961C-4861-A3FE-9904E5177CE3

P1476

Q37098243-F721FE28-C58F-4C6A-93C3-BC5C0C6B8B9F

P2093

Q37098243-AD5A9F6E-17F1-4FB4-8ED1-46EFCACB4219

Q37098243-B8725613-FD38-48AE-AA7E-E1A7775E27E9

Q37098243-C7D6F757-6860-44A3-A6BA-35F780E55E52

Q37098243-CE220C86-090F-4239-9BF6-D844740AE316

Q37098243-D8659D12-2356-4433-A4C1-21B30D0664E7

Q37098243-EB649099-D697-43A5-9CED-2A2D85021540

P2860

Q37098243-03E85501-07AA-4C62-9633-8DB4B53E84E8

Q37098243-119E6F24-22D4-4B57-81D3-07D6F0594CFE

Q37098243-1535B70D-469B-4DD3-B236-5D24711E360F

Q37098243-1976FEAB-C7B8-4502-8EC0-4F30299C30D6

Q37098243-251EE095-C19D-4800-84BD-22CBD7838F65

Q37098243-3C24AE67-D1EB-49AB-98BA-453215CB19F9

Q37098243-3DBC8070-D9DA-4CC4-BB67-DD174FD939C8

Q37098243-4DF8D6CE-3A62-439D-BC3E-5FE0AAFC8500

Q37098243-513B16CA-CDD6-4A05-A1E0-73CDDC24F4E8

Q37098243-613FDCD4-71FF-49BB-93E5-016F974163AB

P304

Q37098243-E238E3BF-CA04-4E1D-A904-83404D3AE005

P31

Q37098243-19C2BE9A-B024-4108-A278-EC1C025B3D7D

P356

Q37098243-3B27AEBE-1429-4F20-B216-3B0D2B551F45

P433

Q37098243-ED7C465A-8ADB-4080-A192-F8A2FDE85D39

P478

Q37098243-213E7929-5421-43CB-BDA3-2690FCE52324

P577

Q37098243-E29D8EE0-6288-43D1-827C-DFA05A9C0A06

P698

Q37098243-7D6D4A27-4149-4145-9D51-13E13155FBEB

P932

Q37098243-0592B23E-8035-4BB0-8BED-ECD97954944A

P356

S0828-282X(08)70597-X

P1433

The Canadian Journal of Cardiology

P1476

How many cardiovascular events ...... gement of high-risk Canadians?

@en

P2093

Anatoly Langer

http://www.w3.org/2001/XMLSchema#string

Cheryl L Attard

http://www.w3.org/2001/XMLSchema#string

Chi-Ming Chow

http://www.w3.org/2001/XMLSchema#string

Daniel T Grima

http://www.w3.org/2001/XMLSchema#string

Lawrence A Leiter

http://www.w3.org/2001/XMLSchema#string

Shaun G Goodman

http://www.w3.org/2001/XMLSchema#string

P2860

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update

Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses

Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis

Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease

Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence

Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis

Processes and outcomes of care for diabetic acute myocardial infarction patients in Ontario: do physicians undertreat?

Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis

A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone

P304

363-368

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0828-282X(08)70597-X

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P577

2008-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18464939

http://www.w3.org/2001/XMLSchema#string

P932

2643136

http://www.w3.org/2001/XMLSchema#string